Loading…
← CockpitCompetitor Analysis › 300009.SZ Anhui Anke Biotechnology (Group) Co., Ltd. Class AOpen in the cockpit ↗

Anhui Anke Biotechnology (Group) Co., Ltd. Class A300009.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Leading Chinese maker of recombinant human growth hormone (rhGH) and other biologic drugs.

≈ A Chinese Genentech/Novo Nordisk for growth hormoneMomentum strong 70
Mkt cap
$1.88B
US dollars, full cap
Free float
83%
of shares outstanding
$/day
$16.2M
20-day average traded
Fwd P/E
18.1×
forward earnings
ROIC−WACC
+10.0 pp
WACC 9.1%
Hurdle
-1 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥7.56
1D-0.9%
1W-5.3%
1M-5.8%
3M-13.9%
6M-12.5%
YTD-21.0%
1Y-30.3%
ATR %2.4%
52w lowhigh34.4% off high

What Anhui Anke Biotechnology (Group) does

Leading Chinese maker of recombinant human growth hormone (rhGH) and other biologic drugs.

In one line: A Chinese Genentech/Novo Nordisk for growth hormone.

Products and services

  • Recombinant human growth hormone
  • Other biologic drugs

Customers

  • Hospitals/pediatric endocrinologists

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Recombinant growth hormone & biologics

What could go right

  • Growth-hormone deficiency treatment demand

What could go wrong

  • Centralized procurement price cuts
  • Competition from long-acting rival formulations

Moat: narrow (regulatory licence, brand, scale). Long-standing leadership and manufacturing scale in China's growth-hormone market.

Headquarters: Hefei, Anhui, China · Employees: 2,505

Named competitors

Anhui Anke Biotechnology (Group) at a glance

Size Anhui Anke Biotechnology (Group) (300009.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.88B, the 1229th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.56 on 18 Nov 2026.

Performance Over six months the shares fell 12.5%, against -7.3% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue fell 9.4% over the last twelve months (peer median +11.8%); the operating margin is 30.0% (peer median 13.3%).

Valuation It trades at 18.1× forward earnings against a peer median of 18.4× (10th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 10.0 points above its cost of capital (9.1% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026Peer median 95300009.SZ 89
Six months, rebased to 100: Anhui Anke Biotechnology (Group) against the median of its 20 peers (local-currency closes).

Anhui Anke Biotechnology (Group) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.34BCN¥2.63BCN¥2.52BCN¥2.85BCN¥2.32B
Revenue growth—+4%-11%+23%—
Gross profitCN¥1.82BCN¥1.95BCN¥1.91BCN¥2.19BCN¥1.77B
EBITDAn/aCN¥912MCN¥863MCN¥1.01BCN¥872M
Net incomeCN¥652MCN¥735MCN¥707MCN¥847MCN¥703M
Free cash flowCN¥551MCN¥760MCN¥607MCN¥790MCN¥251M
Capital expenditureCN¥152MCN¥127MCN¥117MCN¥195MCN¥474M
Total debtCN¥94.6MCN¥76.1MCN¥152MCN¥262MCN¥208M

Quarterly statements and history in the cockpit →

Anhui Anke Biotechnology (Group) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%PFIZER600211COHANCEALIVUS000908DMPSHILPAMED05123005734540600201605507HRMY000028ONESOURCEBHVNZYMERARE301015002399300009.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Anhui Anke Biotechnology (Group) is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%+100%0×50×100×150×PFIZER600211COHANCEDMPSHILPAMED0512600201605507HRMYONESOURCEZYME301015300009.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Anhui Anke Biotechnology (Group) is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%PFIZER600211ALIVUSDMP0512300573600201605507HRMY000028301015002399300009.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Anhui Anke Biotechnology (Group) is the large dot.

Anhui Anke Biotechnology (Group) competitors and peer comparison

Head to head with its named competitors (300009.SZ vs 000661.SZ vs NOVO-B.CO vs PFE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Anhui Anke Biotechnology (Group) 300009.SZ$1.88B-12%-9%30%18.1×8.0%
Changchun High-Tech Industry (Group) 000661.SZ$4.52B-13%-18%-1%30.3×32.4%
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%11.8×-0.5%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Merck KGaA MRK.DE$71.3B+16%+1%19%17.4×7.4%
Ascendis Pharma A/S ASND$16.9B+12%+94%18%28.0×19.2%

How Anhui Anke Biotechnology (Group) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Anhui Anke Biotechnology (Group) against its 20 peers (data as of 18 Nov 2026)
Measure300009.SZPeer medianRank in peer set
1-month return-5.8%+1.7%6th lowest of 21
6-month return-12.5%-7.3%9th lowest of 21
Distance from 52-week high-34.4%-27.6%7th lowest of 21
Revenue growth (TTM)-9.4%+11.8%lowest of 20
Operating margin30.0%13.3%4th highest of 20
Forward P/E18.1×18.4×10th cheapest of 19
Growth the price implies (Req g, 7 yrs)8.0%0.3%5th most demanding of 13
Growth delivered (Del g)+9.3%+6.8%5th highest of 13
Hurdle (Req g minus delivered)-1.3 pp-12.1 pp6th most demanding of 13
ROIC minus cost of capital+10.0 pp+0.1 pp6th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Shenzhen Hepalink Pharmaceutical 002399.SZChina$1.80B-12%-6%8%25.8×-0.7%+0.5%

Questions

Who are Anhui Anke Biotechnology (Group)'s main competitors?
Named competitors: Changchun High & New Technology (GeneScience) (000661.SZ), Novo Nordisk (NOVO-B.CO), Pfizer (PFE), Merck KGaA (MRK.DE), Ascendis Pharma (ASND). The cockpit's measured peer set (industry) also includes Pfizer (PFIZER.NS), Tibet Rhodiola Pharmaceutical (600211.SS), Cohance Lifesciences (COHANCE.NS), Alivus Life Sciences (ALIVUS.NS), CSPC Hunan Jingfeng Pharmaceutical (000908.SZ), Dermapharm (DMP.DE).
Is Anhui Anke Biotechnology (Group) expensive compared with its peers?
On forward p/e it trades at 18.1× against a peer median of 18.4×, 10th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Anhui Anke Biotechnology (Group) stock performed?
Over six months to 18 Nov 2026 the shares returned -12.5% against -7.3% for the median peer; over one year -30.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.